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E-mail address: yuwanghk@hku.hk (Y. Wang).Ageing in mammals remains an unsolved mystery. Anti-ageing is a recurring topic in the history of
scientiﬁc research. Lifespan extension evoked by Sir2 protein in lower organisms has attracted a
large amount of interests in the last decade. This review summarizes recent evidence supporting
the role of a Sir2 mammalian homologue, SIRT1 (Silent information regulator T1), in regulating age-
ing and cellular senescence. The various signaling networks responsible for the anti-ageing and
anti-senescence activity of SIRT1 have been discussed. In particular, a counter-balancing model
involving the cross-talks between SIRT1 and AMP-activated protein kinase (AMPK), another stress
and energy sensor, is suggested for controlling the senescence program in mammalian cells.
 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Cellular senescence
Senescence, originating from the Latin word senex, refers to a
physiological program towards permanent cell cycle arrest. The
ﬁrst evidence of cellular senescence dates back to ﬁfty years ago
when Hayﬂick and Moorhead observed that after a limited number
of divisions, embryo-derived ﬁbroblasts entered an irreversible
state of growth arrest [1]. Similar phenomena have been subse-
quently observed in human hepatocytes, keratinocytes, lympho-
cytes, smooth muscle and endothelial cells [2–6], leading to the
concept of ‘Hayﬂick limit’, i.e. the ﬁnite replicative life span or
the restricted cumulative population doubling of somatic cells
in vitro. Morphologically, senescent cells are characterized by cel-
lular enlargement and ﬂattening with a concomitant increase in
the size of the nucleus and nucleoli, augmented number of lyso-
somes and Golgi, and the appearance of vacuoles in the cytoplasm
[7].
For a number of years, the occurrence of senescence in vivo has
been questioned, due mainly to the lack of speciﬁc markers. In
1995, Dimri and colleagues reported that several types of human
senescent cells expressed a b-galactosidase that was detectable
by a histochemical assay at pH 6 [8]. An age-dependent increase
in this senescence-associated b-galactosidase (SA-ß-Gal) stainingchemical Societies. Published by E
harmacology and Pharmacy,
g, 21 Sassoon Rd., Pokfulam,was observed in human skin. On the other hand, this marker was
absent in pre-senescent and quiescent ﬁbroblasts, and terminally
differentiated keratinocytes. Since then, other senescence bio-
markers have been identiﬁed, including telomere attrition [9,10],
active checkpoint kinase ATM [11], heterochromatin proteins
[12], and the cyclin-dependent kinase (CDK) inhibitors p21CIP1
(p21), p16INK4a (p16) and p27KIP1 (p27) [13–16], most of which
are actively participated in pathways that affect cellular senes-
cence. Using these selective markers, an age-dependent increasing
of senescent cells has been validated in various mammal tissues
in vivo [11,17–19]. Cellular senescence is now considered to be
the hallmark of mammalian ageing.
The physiological roles of senescence remain controversial. In
general, senescence can be viewed as an alternative response
program to cellular stresses and damages that otherwise may
cause programmed cell death [20]. When confronted with meta-
bolic (e.g. hyperglycemia) and/or environmental stressors (e.g.
oxidative stress), a self-protective mechanism of senescence
may be initiated to halt the energy-consuming process of cell
proliferation. However, a feedback-regulation should be in place
to prevent cellular senescence from becoming irreversible (as is
the case with terminal ageing of the organism), which, most of
the time is independent of the initial stress conditions. The dura-
tion of cell survival in the non-dividing state after cessation of
proliferation is also a characteristic of longevity [21]. The fate
of senescent cells in the living organism is largely unknown.
The persistent presence of senescent cells can exert adverse ef-
fects on tissue functions, thus representing a pivotal underlyinglsevier B.V. All rights reserved.
Fig. 1. SIRT1 elicits the anti-senescence activity by targeting a wide range of protein
substrates that are critically involved in regulating key cellular processes, such as
oxidative stresses, DNA damage, mitochondrial biogenesis and autophagy.
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ple, in healthy postnatal tissues, the endothelial cells (referring to
those line the inner surface of blood vessels) are mostly quies-
cent and rarely proliferate. In response to vascular injury, tissue
ischemia, or other stress conditions, a remarkable phenotypic
plasticity allows them to proliferate rapidly. However, their
regenerative capacities declines progressively and coincides with
the development of senescence [23]. Senescent endothelial cells
in vascular lesions release less available nitric oxide for vasodila-
tor regulation, and become pro-inﬂammatory, pro-thrombotic
and pro-atherosclerotic, which accelerate the development of
cardiovascular diseases [24,25].
In addition to acting as a barrier of unlimited cell growth and
division, senescence functions as a tumor suppressive mechanism
to restrict excessive cell growth. Senescent cells are present in pre-
malignant tissues [26]. Escaping from senescence, or immortality,
is important for malignant transformation [26–29]. However, the
additional levels of complexity suggest that senescence functions
as a biological ‘double edged sword’ during tumorigenesis. On
the one hand, it prevents activated oncogenes from initiating a
clone of neoplastic cells and limit the replicative capacity of an
incipient tumor cell [30,31]. On the other hand, although senescent
cells themselves cannot become neoplastic, they promote the
growth of nearby preneoplastic cells and in this way may contrib-
ute to the age-related increase in tumor incidence [32,33].
2. Sirtuins – the longevity regulator
Sirtuins are a family of NAD+-dependent protein deacetylases
that exert multiple cellular functions by interacting with, and
deacetylating a wide range of signaling molecules, transcription
factors, histones and enzymes [34–36]. Sir2 (silent information reg-
ulator 2), the ﬁrst gene discovered in this family, was originally
shown to regulate transcriptional silencing at cell-mating loci,
telomeres, and ribosomal DNA (rDNA) in yeast, through deacetyla-
tion of the epsilon-amino groups of lysines in the amino-terminal
domains of histones [37–42]. The anti-ageing effects of Sir2 was
ﬁrstly demonstrated by Kaeberlein et al, who showed that the
integration of extra copies of Sir2 extended lifespan up to 30% in
Saccharomyces cerevisiae [43]. Similar effects of Sir2 on lifespan
extension were subsequently observed in Caenorhabditis elegans
and Drosophila melanogaster [44–47].
Sirtuins are highly conserved during the evolution from bacteria
to humans. In mammals, the family is represented by seven
members assigned as SIRT1-7, which share the catalytic domain
of 275 amino acids with Sir2 [48–51]. SIRT1-7 show diversecellular localizations. SIRT6 and SIRT7 are localized in the nucleus,
while SIRT3, SIRT4 and SIRT5 reside in the mitochondria. [51].
SIRT1 and SIRT2 shuttle between the cytoplasm and the nucleus.
Mammalian sirtuins have been implicated in a wide range of bio-
logical processes, including metabolism, cell survival, develop-
ment, chromatin dynamics and DNA repair. SIRT1 is the
mammalian ortholog most highly related to Sir2. Protein expres-
sion and transcription levels of SIRT1 decline with ageing in ani-
mals and human tissues, including lung, fat, heart and blood
vessels [52–54]. Sirtuins have attracted considerable interest be-
cause of their role as the longevity regulator and their therapeutic
potentials for the prevention/treatment of ageing-associated med-
ical complications, in particular cardiovascular diseases, diabetes
and neurodegenerative disorders.
In 1935, McCay and co-workers reported that long-term caloric
restriction without malnutrition almost doubled lifespan in rats
[55]. This lifespan-extending effect of caloric restriction has been
conﬁrmed in a wide range of organisms ranging from yeast to ro-
dents, and primates [56–60]. These observations lead to the con-
cept that caloric restriction regulates lifespan by reducing the
metabolic rate and thus diminishing the accumulation of macro-
molecule damage over time. In higher organisms, caloric restric-
tion is the only non-genetic intervention capable of promoting
longevity and reducing the incidence of age-related disorders, such
as diabetes, cardiovascular disease, and cancer. Both Sir2 and SIRT1
have been implicated in the anti-ageing activity of caloric restric-
tion. Decreasing the expression of Sir2 blocks the lifespan-extend-
ing effect of caloric restriction in S. cerevisiae and Drosophila
[46,61]. Likewise, in rodents, caloric restriction stimulates SIRT1
expression in a variety of tissues, including brain, visceral fat, kid-
ney and liver [56]. Mice lacking SIRT1 fail to show an increased
activity in response to caloric restriction [62]. By contrast, eleva-
tion of SIRT1 expression results in a beneﬁcial phenotype resem-
bling that of caloric restriction [63–65]. Despite these suggestive
ﬁndings, there is yet no foolproof evidence that mammalian
sirtuins are either indispensible or sufﬁcient to lifespan extension
in response to caloric restriction. In fact, the available evidence
suggests that sirtuins mediate the anti-ageing effects of caloric
restriction largely by regulating cellular energy metabolism in
ways that directly beneﬁt normal physiology [66–70].3. Sirtuins and senescence in mammalian cells
In yeast, senescence is characterized by the accumulation of
extrachomosomal rDNA circles (ERCs), which occurs in mother
cells as they go through successive cell divisions [71]. The Sir2 pro-
tein acts as a transcriptional silencer to suppress ERC formation,
and as a consequence, increases longevity. The ﬁrst evidence that
sirtuins regulate mammalian cellular senescence was provided
by Langley and colleagues, using the primary mouse embryonic
ﬁbroblasts as a model system [72]. SIRT1 antagonizes premature
cellular senescence, induced by pro-myelocytic leukemia protein,
by interacting with and deacetylating p53. Subsequently, the
anti-senescence effects of SIRT1 have been demonstrated in other
cell types, including human cancer cells (breast cancer MCF-7, lung
cancer H1299 and prostate cancer cells) [73,74], human diploid
ﬁbroblasts [75] and a human umbilical vein endothelial cell line
(HUVEC) [76–78]. In most of these studies, when the effects of
SIRT1 are prevented with speciﬁc pharmacological inhibitors or
siRNA, a premature senescence-like phenotype can be observed.
Conversely, overexpression or activation of SIRT1 prevents both
stress- and replication-induced cellular senescence. In HUVECs,
cellular senescence occurs in parallel with an increased expression
of plasminogen activator inhibitor-1(PAI-1) and a decrease in that
of endothelial nitric oxide synthase (eNOS). SIRT1 exerts protective
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duced premature senescence and deranged expression of PAI-1
and eNOS [76]. Cilostazol, a selective cAMP phosphodiesterase 3
inhibitor, exerts protective effects against endothelial senescence
and dysfunction through upregulation of SIRT1, whereas sirolimus
and everolimus induce endothelial senescence involving down-
regulation of SIRT1 [77,78]. The latter studies suggest that p53
might be of the utmost importance in mediating the senescence
signaling and the protective effect of SIRT1. By contrast, it is not
conclusive whether or not eNOS activation is directly involved in
the anti-senescence activity of SIRT1, although the bioavailability
of nitric oxide is impaired when SIRT1 is down-regulated [76].
Nevertheless, the increase in eNOS expression caused by caloric
restriction is associated with mitochondrial biogenesis and en-
hanced expression of SIRT1 [79], whereas SIRT1 deacetylates and
activates eNOS [80], indicating that a positive feedback mechanism
exists between these two signaling molecules.
Endothelial regeneration is essential to maintain the functional-
ity of the vasculature, in particular after mechanical endothelial in-
jury and ischemia or during wound healing [81]. SIRT1 is highly
expressed in the vasculature and regulates the proliferative activ-
ity of endothelial cells during tissue regeneration [82,83]. It has
been implicated in the regeneration and proliferation of endothe-
lial progenitor cells (EPCs) [83,84]. Exposure to high glucose accel-
erates EPC senescence and decreases EPC number, which is
accompanied by a reduced SIRT1 expression and activity. Knock-
down of SIRT1 with siRNA results in diminished EPC angiogenesis
and increased senescence. SIRT1 controls the angiogenic activity of
endothelial cells via a deacetylation-dependent inactivation of
forkhead box O transcription factors 1 (FoxO1), a crucial negative
transcriptional regulator of blood vessel development [82,85,86].
The acetylation of FoxO1 in EPC is increased signiﬁcantly following
exposure to high glucose. Resveratrol reduces, whereas inhibitors
of SIRT1 (nicotinamide and suramine) potentiate the acetylation
[83]. SIRT1 also deacetylates FoxO3 and/or FoxO4, attenuating
FoxO-induced apoptosis and potentiating FoxO-induced cell-cycle
arrest [87–89]. While the implications of these FoxO modiﬁcations
are still uncertain, it appears overall that deacetylation of FoxO
proteins by SIRT1 promotes cell survival under stress conditions.
During the process of replicative senescence in primary porcine
aortic endothelial cells, both mRNA and protein expressions of
SIRT1 are progressively decreased [53]. Overexpression of SIRT1
stimulates proliferation and prevents senescence by targeting the
tumor suppressor kinase LKB1. In these cells, LKB1 promotes cellu-
lar senescence and retards endothelial proliferation through acti-
vation of AMPK, a master regulator of energy metabolism. SIRT1
is activated by increases in NAD/NADH ratio [90,91], whereas
AMPK senses AMP/ATP levels through its upstream kinase LKB1
[92,93]. A cross-regulation of these two pivotal energy- and
stress-sensor pathways has been implied in the context of endo-
thelial ageing [23]. The endothelium-speciﬁc elevation of SIRT1
activity protects mice from developing drug-induced premature
vascular senescence [53]. There are presumably various interac-
tions between the SIRT1 and AMPK pathways [94–97]. However,
the precise connections between these two nutrient sensing en-
zymes in cellular senescence are largely uncharacterized and war-
rant further investigations.
In addition to SIRT1, SIRT6, a mammalian sirtuin associated
with heterochromatic regions and nucleoli [98], has also been
implicated in the regulation of cellular senescence. Indeed, SIRT6
depletion in mice leads to premature cellular senescence and telo-
mere dysfunction with end-to-end chromosomal fusions, a pattern
resembling the defects observed in Werner syndrome, a human
premature ageing disease [99]. SIRT6 modulates genome stability
by interacting with and deacetylating histone H3 at telometic
chromatin [100]. It also regulates CtIP [C-terminal binding protein(CtBP) interacting protein] to facilitate DNA end resection at the
double-strand breaks (DSB) [101]. Moreover, SIRT6 forms a macro-
molecular complex with DNA-PK [DNA-dependent protein kinase]
and promotes DSB repair [102]. The NFjB RelA subunit is also reg-
ulated by SIRT6, which enhances the NFjB-dependent gene
expression changes involved in cellular senescence [103]. Mecha-
nisms other than these have also been suggested to mediate the
regulatory effects of this protein on energy metabolism in enhanc-
ing insulin signaling and glucose uptake [104]. Effects of other sir-
tuins, in particular SIRT2 and SIRT7, on mammalian ageing have
also been proposed [105–108]. However, the functional relation-
ship among these members of the sirtuin family remains poorly
understood at this stage.4. Anti-senescence activity of SIRT1 – focus on the cross-talks
with AMPK signaling pathway
SIRT1 elicits its various effects by regulating the acetylation/
deacetylation status of a wide range of protein targets involved
in heterochromatin silencing, cycle progression, cell survival and
metabolism [72,88,91,109–112]. By binding with and deacetylat-
ing the target proteins, SIRT1 is able to regulate their activities,
intracellular localizations, stabilities and posttranslational modiﬁ-
cations. With respect to cellular senescence, the plethora of sub-
strates that SIRT1 targets for deacetylation includes p53, NFjB,
PGC-1a [peroxisome proliferator-activated receptor-c coactivator
1a], eNOS, mTOR and FoxOs (Fig. 1). The tumor suppressor p53 is
among the ﬁrst non-histone substrates identiﬁed to be functionally
involved in the anti-senescence activity of SIRT1 [72]. Activation of
the p53-p21 pathway acts as a major mediator of cellular senes-
cence [113]. Deacetylation of p53 by SIRT1 results in an inhibition
of DNA damage- and stress-mediated cellular senescence [114].
NF-jB is a major culprit that mediates ageing-associated pro-
inﬂammatory responses [115]. Oxidative stress and reactive oxy-
gen species (ROS) production modulates the promoter binding
activity of NF-jB, which promotes cellular senescence by transac-
tivating the expressions of cell cycle regulators [116]. SIRT1 phys-
ically interacts with the RelA/p65 subunit of NFjB and inhibits the
transactivation potential of this protein [112]. Mitochondrial func-
tion changes during cellular senescence lead to metabolic inefﬁ-
ciency and increased generation of ROS [117]. SIRT1 promotes
mitochondrial functions and reduces the production of ROS
through regulating the master controller of mitochondrial biogen-
esis, PGC-1a, and the eNOS- and nitric oxide-dependent pathway
[118,119]. A number of SIRT1 targets, including mTOR and FoxOs,
are coordinately involved in the process of autophagy, a house-
keeping process for maintaining energy balance via self-digestion
[120,121]. The extension of lifespan by SIRT1 has been linked to
the efﬁcient maintenance of autophagic degradation, either di-
rectly or indirectly through a downstream signaling network
[122,123].
Mammalian senescence is triggered by a complex signaling net-
work involving the interactions of multiple proteins [19]. Unlike
Sir2 in yeast, which functions exclusively in the nucleoli and het-
erochromatic regions, nucleocytoplasmic shuttling of SIRT1 has
been demonstrated in various mammalian cellular systems
[98,124–127]. Thus, when attempting to unravel the molecular
events upstream and downstream of the SIRT1 pathway in regulat-
ing cellular senescence, one has to consider searching far beyond
the border of nucleus or any single cellular compartment, and cov-
er not only long-term DNA damages and telomere shortening, but
also short-termmetabolic adaptations. In that context, the remain-
der of this article will attempt to elucidate the interplays between
SIRT1 and LKB1/AMPK signaling, the two well-known stress resis-
tance and longevity-regulating pathways.
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AMPK is the primary regulator of cellular responses to reduced
ATP levels and acts as a sensor to maintain the energy balance
within a cell [128,129]. In general, activation of AMPK down-regu-
lates synthetic pathways such as protein, fatty acid and cholesterol
biosynthesis, yet switches on the catabolic pathways that generate
ATP, such as fatty acid oxidation, glucose uptake and glycolysis. It
achieves this not only through direct phosphorylation of a variety
of key metabolic enzymes, but also by altering gene expressions in
a tissue-speciﬁc manner [130,131]. Depending on the tissue types,
the targeted genes include PGC-1a, the FoxO family of transcrip-
tion factors, SREBP [sterol regulatory element binding protein]
and ChREBP [carbohydrate response element binding protein].
AMPK is a trimeric serine/threonine protein kinase comprising a
catalytic a subunit and non-catalytic b and c subunits. The a sub-
unit contains an NH2-terminal catalytic kinase domain and a
COOH-terminal regulatory domain to which the b and c subunits
bind. The c subunits contain four tandem repeats of a sequence
motif ‘‘CBS domain’’, which represents the regulatory AMP- and
ATP-binding sites of the AMPK complex. Stresses (e.g. metabolic
poisoning, free radical production, heat-shock, hypoxia, or nutrient
deprivation) that cause a rise in AMP/ATP ratio can activate AMPK,
by facilitating phosphorylation of the a subunit at a speciﬁc resi-
due (Thr172) located within the activation loop. This process can
cause at least 50- to 100-fold activation of AMPK and is mediated
by upstream kinases (AMPKK), one of which is the tumor suppres-
sor LKB1 [92]. This complex regulatory system results in a superb
sensitivity of AMPK to respond to even a very small change in AMP
levels.
LKB1 is a serine/threonine protein kinase possessing prolifera-
tion-inhibitory and anti-tumor activities. It was originally
discovered as a tumor suppressor gene mutated in patients with
Peutz-Jeghers syndrome, a dominantly inherited human disorder
characterized by an increased predisposition to cancer [132,133].
Loss-of-function of LKB1 is frequently found in non-small cell lung
carcinomas [134]. Inactivation of LKB1 has also been reported in
pancreatic cancers, melanomas, prostate, endometrial and cervical
cancers, papillary breast cancers, testicular cancers, as well as
colon and gastric cancers [135–137]. Overexpression of LKB1
suppresses cancer cell growth by inducing a G1 cell cycle arrest
[138,139]. LKB1 is not only considered to be a tumor suppressor
kinase that regulates cell proliferation, but also actively involved
in controlling cell motility, metabolism, polarity and senescence
[140–142].
LKB1 mediates AMPK activation in response to various cellular
stresses- and pharmacological agents [143–150]. While activation
of LKB1/AMPK signaling protects cells against energy stress by
maintaining energy homeostasis and ensuring a slow consumption
of energy stores [151,152], this pathway can also cause cellular
senescence, cell cycle arrest and apoptosis in eukaryotic systems
[153,154]. In another word, a certain level of AMPK activation is
beneﬁcial, whereas over-activation may be destructive. For exam-
ple, mild energy restriction promotes AMPK activation and triggers
neurogenesis, whereas severe diet restriction-induced AMPK leads
to neuroapoptosis, possibly due to insufﬁcient cell resources to re-
verse AMP:ATP ratio [155]. LKB1 is signiﬁcantly up-regulated in
senescent primary endothelial cells and overexpression of this ki-
nase induces senescence through AMPK activation in young cells
[53]. LKB1 deﬁciency prevents culture-induced senescence in mur-
ine embryonic ﬁbroblasts [156]. In senescent ﬁbroblasts, AMP:ATP
ratios are two to three folds higher than those in young ﬁbroblasts,
and senescence is accompanied by a marked elevation in AMPK
activity [157,158]. In mice, caloric restriction down-regulates
AMPK activity in the liver [159]. Activation of LKB1/AMPK and
inhibition of mTOR contribute to the premature ageing phenotypeof Zmpste24/ mice [153]. AMPK hyper-activation has also been
reported in the skeletal muscle and liver of old rodents
[160,161]. In the aorta of old mice, LKB1 and phosphorylated
AMPK(Thr172) levels are much higher than those of young mice
[53]. The regulation of ageing by AMPK is evolutionarily preserved.
In yeast, the AMPK homologue Snf1 is a pivotal regulator of glu-
cose-related gene expression at times of low fuel availability
[162]. Snf1 is a heterotrimer composed of a catalytic a subunit
(Snf1p) that phosphorylates target proteins at Ser/Thr residues,
an activating c subunit (Snf4p), and a b subunit (Sip1p, Sip2p, or
Gal83). snf1 null mutants are viable, but are unable to grow on su-
crose, galactose, maltose, melibiose or non-fermentable carbon
sources and do not contain any detectable peroxisomes, whereas
overproduction of Snf1p causes accelerated ageing [163]. Loss of
Snf4p, an activator of Snf1p, extends generational life span
whereas loss of Sip2p, a presumed repressor of the kinase, causes
an accelerated ageing [164].
In summary, these ﬁndings suggest that chronic activation of
the LKB1-AMPK catabolic pathway may turn an originally pro-
survival strategy into a pre-ageing mechanism and contribute to
the progressive degeneration during cellular senescence.
4.2. Reciprocal regulations of SIRT1 and LKB1/AMPK signaling in
cellular senescence
Interactions between SIRT1 and AMPK pathways occur in differ-
ent types of tissues and cells [95,97,165–172]. In liver, while AMPK
and SIRT1 may act in an autoregulatory loop to regulate lipid
metabolism, their impacts on gluconeogenesis during fasting con-
ditions appear to diverge [165]. In skeletal muscle, AMPK enhances
SIRT1 activity by increasing cellular NAD+ levels [94,173], and this
ampliﬁcation of SIRT1 and its downstream signaling pathways is
impaired in AMPK-deﬁcient states [171]. In neuronal systems, res-
veratrol-stimulated AMPK activity depends on LKB1 but does not
require SIRT1 [174]. However, other results suggest that resvera-
trol activates LKB1/AMPK signaling in both SIRT1-dependent and
independent manners in HepG2 cells [95,175]. In HEK293 cells,
over-expression of SIRT1 activates AMPK through LKB1 [96]. It
should be noted that the regulations of growth, survival, energy
metabolism and response to stresses in cancer tissues are very dif-
ferent from those of normal cells. Cells from SIRT1 knockout mice
show either no change [174] or an increase in AMPK activity
[97,176,177]. Taken in conjunction, the available evidence suggests
that AMPK and SIRT1 are vital links in an orchestrated network
controlling cellular homeostasis. Therefore, it is of great impor-
tance to understand the mechanisms by which they interact and
the consequences of the cross-regulations under various
conditions.
In endothelial cells, LKB1- and AMPK-induced senescence can
be prevented by increasing the levels of SIRT1 [53]. By contrast,
inhibition of SIRT1 activity or over-expression of a dominant neg-
ative deacetylase mutant, SIRT1(H363Y), induces endothelial
senescence and elevates the protein levels of LKB1, resulting in a
hyperactivation of AMPK [53]. These observations demonstrate
the link between the anti-senescence activity of SIRT1 and the
deregulation of LKB1/AMPK signaling [23]. Under normal physio-
logical conditions, LKB1 is constitutively active [131], which makes
it necessary to have a counter-mechanism available to prevent per-
sistent or exaggerated activation of AMPK signaling. The regulation
by SIRT1 of LKB1 protein stability represents such a counterbalanc-
ing mechanism (Fig. 2). Deacetylation mediated by SIRT1 synergiz-
es with the ubiquintination and degradation of LKB1 [53]. Because
both acetylation and ubiquitination occur on lysine residues,
deacetylation of LKB1 by SIRT1 may control the accessibility of
these residues for ubiquitination and thereby alter its stability in
endothelial cells. However, how deacetylation affects the biological
Fig. 2. Several potential molecular pathways are involved in cellular senescence
caused by hyperactivated LKB1/AMPK signaling.
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kinase domain is poorly related to other protein kinases. In partic-
ular, the NH2- and COOH-terminal non-catalytic regions of LKB1
possess no identiﬁable functional domains. LKB1 shuttles between
the nucleus and the cytoplasm [178]. When LKB1 is forced to
remain in the cytoplasm by disruption of the nuclear localization
signal, it retains full growth-suppression activity in a kinase-
dependent manner [139]. It is highly possible that acetylation/
deacetylation of speciﬁc residues by SIRT1 affect the intracellular
localization, protein stability and/or protein-protein interactions
of LKB1 in primary endothelial cells. Several other molecules in-
volved in regulating senescence, including p53 and FoxOs, are also
modulated by reversible acetylation and targeted by SIRT1
[72,179]. Changes in lysine acetylation may represent an important
mechanism integrating metabolic and stress signals to govern cel-
lular senescence and ageing.
Cell cycle regulation by AMPK is mediated by inhibition of the
TSC2-mTOR (mammalian target of rapamycin) pathway as well
as up-regulation of the p53-p21 axis [180,181] (Fig. 2). The mTOR
pathway is a major controller of protein biosynthetic processes.
Blockage of this pathway induces protein degradation through
autophagy and the ubiquitin-proteasome system [131]. Premature
ageing activates a systemic metabolic response involving induction
of autophagy [153]. Actually, the physiological ageing process is
associated with a declined efﬁciency of autophagic degradation
[121]. Although both SIRT1 and AMPK are implicated in the regu-
lation of autophagy [176,182,183], the detailed interactions and
the involvement of mTOR or other signaling molecules, such as
FoxOs, NFjB and p53, remain to be elucidated. Opposing effects
of the two signaling molecules have been reported in relation to
p53 regulation. Persistent activation of AMPK leads to acceleratedFig. 3. A model represents the reciprocal regulations of SIRT1 and AMPK pathways in m
senescence is accompanied by a decreased SIRT1 expression and activity, and an augmen
kinase LKB1. A possible feed-back regulation of SIRT1 by AMPK is suggested for furtherp53-dependent cellular senescence [180], whereas SIRT1 antago-
nizes p53-induced cellular senescence through promoting its
deacetylation [72]. LKB1 acts as an upstream kinase for PTEN
(phosphatase and tensin homologue), which overcomes growth/
survival signaling from the PI3K/Akt pathway [184]. The balance
between LKB1-AMPK and PI3K/Akt pathways may determine cell
growth or death in response to the nutritional status and stress
[185]. The cross-talks between SIRT1 and AMPK in controlling
senescence could also converge at the level of PI3K/Akt signaling
[53].
Unlike in the metabolic organ skeletal muscle, AMPK does not
affect the NAD+ biosynthetic enzyme, NAMPT [nicotinamide phos-
phoribosyltransferase], in endothelial cells [53]. Moreover, NAMPT
expression is not different in senescent cells from that of young
cells. These ﬁndings, however, cannot exclude other mechanisms
that may be involved in the regulation of SIRT1 by AMPK, such
as those at the posttranscriptional levels (Fig. 2). For example,
SIRT1 mRNA levels are regulated by the RNA binding protein
HuR and by microRNA, which repress SIRT1 protein expression in
response to different stress conditions [186–188]. Depending on
the upstream signal, HuR causes SIRT1 mRNA to be either stabi-
lized or degraded. During the progression of cellular senescence,
the mRNA and protein levels of SIRT1 decrease progressively
[53]. AMPK activation causes premature ﬁbroblast senescence
through a mechanism that involves HuR [157,189]. Moreover,
AMPK inhibits the transport of HuR to the cytoplasm and thus
blocks its ability to stabilize and enhance the expression of target
mRNAs [189]. HuR levels are lower in senescent cells, and the
over-expression of HuR restores a ‘‘younger’’ phenotype, whereas
a reduction in HuR expression accentuates the senescent appear-
ance [190]. Taken in conjunction, these studies are consistent with
a role of HuR, possibly involving AMPK, in regulating the mRNA
levels of SIRT1 during the process of replicative senescence.
5. Concluding remarks
Energy metabolism and metabolic regulators play pivotal roles
in controlling longevity and cellular senescence. SIRT1 and LKB1/
AMPK are the two key energy sensor systems regulating cell sur-
vival, proliferation and senescence. While acute activation of the
LKB1/AMPK catabolic pathway permits a rapid adaption or resis-
tance to external and internal stresses, sustained stimulation of
the same pathway leads the cells toward a condition of irreversible
senescence, which is detrimental to normal physiological func-
tions. The anti-ageing activity of SIRT1 is achieved at least in partammalian cellular senescence. The progression from pre-senescence to irreversible
ted AMPK function. SIRT1 counter-regulates AMPK through targeting the upstream
investigations.
Y. Wang et al. / FEBS Letters 585 (2011) 986–994 991by ﬁne-tuning the LKB1/AMPK pathway and preventing the transi-
tion of an originally pro-survival program into a pro-ageing mech-
anism, which results in systemic degeneration (Fig. 3). This process
is elegantly controlled by a complex network involving many sig-
naling proteins, as well as by the ratios between low molecular
weight metabolites (e.g. NAD/NADH and AMP/ATP). Further stud-
ies on the reciprocal regulatory mechanisms and the unexplored
pathways responsible for the dysregulated balance between SIRT1
and LKB1/AMPK signaling may provide important insights for tem-
poral and quantitative control of the ageing process.
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